胃癌雌激素受体和孕激素受体的检测及临床意义

Expression and Significance of Estrogen Receptor and Progesterone Receptor in Gastric Cancer

目的：为了研究雌激素受体（Ｅｓｔｒｏｇｅｎ ｒｅｃｅｐｔｏｒ，ＥＲ）和孕激素受体（Ｐｒｏｇｅｓｔｅｒｏｎｅ ｒｅｃｅｐｔｏｒ，ＰｇＲ）在胃癌中的表达以及与临床病理学之间的关系。方法；我们采用免疫组织化学法对９１例胃癌作了测定。结果：９１例胃癌的 ＥＲ、ＰｇＲ阳性率分别为 ３９．６ ％。、４１．８％，在９１例胃癌中，分化好的腺癌细胞 ＥＲ、ＰｇＲ阳性率均为 ４７．９％，高于分化差的癌细胞的 ＥＲ、ＰｇＲ阳性率（３０．２％和 ３４．９％）（Ｐ＜０．０５）．淋巴结转移胃癌病人的 ＥＲ、ＰｇＲ阳性率（５０．６％、４９％）明显高于无淋巴结转移的胃癌病人的 ＥＲ、ＰｇＲ阳性率（２２．２％、２５．９％）（Ｐ＜０．０５）．发病年龄和性别与 ＥＲ、ＰｇＲ均无关。结论：ＥＲ阳性的胃癌是预后较差的肿瘤，胃癌（尤其是有淋巴结转移的胃癌）的抗雌激素治疗可能有良好的前景。

Purpose: To study expression of Estrogen receptor(ER) and Progesterone receptor(PgR) in gastric cancer and association between ER, PgR and clinicopathologic parameters. Methods: Immunohisto- Immunohistochemical ABC method was employed to detect ER, PgR in 91 formalin-fixed, paraffin specimens of gastric cancer. Results: Positive rates of ER, PgR in gastric cancer were 39.6% and 41.5% . The positive rates of ER, PgR in well differentiated adenocarcinoma cell were 47w. 9% and 47. 9% while 30. 2% and 34. 9% in poorly differentiated adenocarcinoma cell (P <0.05). The positive rates of ER, PgR in gastric cancer with lymph node metastasis were significantly higher than that in gastric cancer without lymph node metastasis (P<0.05). It is indicated that positive rates of ER, PgR are not any associate with age, sex and invasive depth. Conclusion: The gastric cancer of ER positive may be poor prognosis and anti-estrogen treatment may provide a new approach in gastric cancer treatment especially in the treatment of gastric cancer with lymph node metastasis.